Cellceutix Corporation (CTIX.OB) says it will "immediately advance" Brilacidin — the defensin-mimetic antibiotic acquired in the recent deal for PolyMedix — to a Phase 2b clinical trial for acute bacterial skin and skin structure infections.
The company also says the compound may be effective for oral mucositis and as such, CTIX plans to finalize an IND and pursue an orphan designation for the treatment.
Ultimately, the company sees quite a few exciting opportunities for the assets acquired from PolyMedix: "We believe we hit a home run with the PolyMedix acquisition, especially as it pertains to Brilacidin. The reality of owning these assets is now beginning to set in." (PR)
More on Brilacidin here